Robert F. Kennedy Jr., the President-elect’s pick for top health official, has clarified his stance on weight-loss drugs and vaccines. In a recent interview with CNBC’s Jim Cramer, Kennedy emphasized that lifestyle changes, such as healthy eating, should be the primary approach to addressing obesity. He also stated that while he was initially critical of GLP-1 weight-loss drugs, they do have a place in treatment plans.
Kennedy’s past criticism of these drugs has raised concerns among investors and pharmaceutical companies. However, it appears his stance is more nuanced, acknowledging lifestyle changes as the first line of response to obesity. The pharmaceutical industry has been closely watching Kennedy’s views, particularly regarding his stance on vaccines.
Contrary to speculation, Kennedy denied being against all vaccines, stating that this assertion was untrue. His comments on vaccines have been met with skepticism in the past, given his previous unfounded claims about their link to autism. Nevertheless, as he prepares to take on a key role in shaping healthcare policy, Kennedy’s clarification on weight-loss drugs and vaccines may help alleviate concerns among stakeholders.
In related news, the market for GLP-1 weight-loss drugs is expected to continue growing, with some analysts predicting a value of at least $100 billion by 2030. Companies like Novo Nordisk and Eli Lilly are leading the charge in this space, with their stocks experiencing significant gains as a result.
Source: https://www.cnbc.com/2024/12/12/rfk-jr-tells-jim-cramer-weight-loss-drugs-shouldnt-replace-healthy-eating-not-against-all-vaccine.html